Inhibition of Tumor Endothelial ERK Activation, Angiogenesis, and Tumor Growth by Sorafenib (BAY43-9006)
- 1 November 2006
- journal article
- Published by Elsevier in The American Journal of Pathology
- Vol. 169 (5) , 1875-1885
- https://doi.org/10.2353/ajpath.2006.050711
Abstract
No abstract availableKeywords
Funding Information
- Molecular Studies of Liver and Digestive Diseases Morphology Core (P30 DK50306)
This publication has 49 references indexed in Scilit:
- Genomic alterations in spontaneous and carcinogen-induced murine melanoma cell linesOncogene, 2004
- Angiopoietin‐1 activates both anti‐ and proapoptotic mitogen‐activated protein kinasesThe FASEB Journal, 2003
- Role for Extracellular Signal-Responsive Kinase-1 and -2 in Retinal AngiogenesisInvestigative Opthalmology & Visual Science, 2003
- RAF/RAS oncogenes and mismatch-repair statusNature, 2002
- Mutations of the BRAF gene in human cancerNature, 2002
- VEGF Prevents Apoptosis of Human Microvascular Endothelial Cells via Opposing Effects on MAPK/ERK and SAPK/JNK SignalingExperimental Cell Research, 1999
- Integrin αvβ3 Requirement for Sustained Mitogen-activated Protein Kinase Activity during AngiogenesisThe Journal of cell biology, 1998
- Basic Fibroblast Growth Factor–Induced Angiogenic Phenotype in Mouse EndotheliumArteriosclerosis, Thrombosis, and Vascular Biology, 1997
- Ordered phosphorylation of p42mapk by MAP kinase kinaseFEBS Letters, 1992
- Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genesPublished by Elsevier ,1988